Skip to main content
Premium Trial:

Request an Annual Quote

Roche, Lonza to Co-distribute MycoTool Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche and Lonza today announced an exclusive co-distribution deal for the commercialization of Roche's MycoTool mycoplasma PCR assays.

As a result, MycoTool kits are now available from Lonza for final release testing for pharmaceutical products upon validation. Lonza also offers contract testing services using the MycoTool test, which is the first commercial nucleic acid testing-based detection system for mycoplasma biosafety testing of approved biological products, the two firms said.

Financial and other terms of the deal were not disclosed.

Release testing with the MycoTool PCR-based test from Roche Custom Biotech has been approved by the European Medicines Agency for several pharmaceutical products. The test is the first commercially available mycoplasma PCR-based test for replacing traditional mycoplasma tests, which use cell-dependent and cell-independent culture methods during pharmaceutical production, Roche and Lonza said.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.